Nuclear factor-κB (NF-κB) is constitutively activated in diverse human malignancies by mechanisms that are not understood 1,2 . The MUC1 oncoprotein is aberrantly overexpressed by most human carcinomas and, similarly to NF-κB, blocks apoptosis and induces transformation [3] [4] [5] [6] . This study demonstrates that overexpression of MUC1 in human carcinoma cells is associated with constitutive activation of NF-κB p65. We show that MUC1 interacts with the highmolecular-weight IκB kinase (IKK) complex in vivo and that the MUC1 cytoplasmic domain binds directly to IKKβ and IKKγ. (Fig. 1a) . Human ZR-75-1 and MCF-7 breast cancer cells that express endogenous MUC1 were stably transfected to express either an empty vector or a MUC1 siRNA 4 ( Supplementary Information, Fig. S1a ). Silencing of MUC1 in ZR-75-1 (ref. 4) and MCF-7 cells 7 decreased nuclear NF-κB p65 (Fig. 1b) . MUC1 expression was also associated with a decrease in cytosolic NF-κB p65 levels in HeLa and ZR-75-1 cells ( Supplementary  Information, Fig. S1b ). To determine whether MUC1 is associated with activation of the NF-κB p65 transcription function, HeLa and ZR-75-1 cells were transfected with a construct containing a NF-κB-binding site upstream of the luciferase reporter (pNF-κB-Luc). MUC1 expression was associated with activation of pNF-κB-Luc (Fig. 1c) . In contrast, MUC1 had no effect on activation of a pNF-κB-Luc construct that was mutated at the NF-κB p65 binding site (Fig. 1c) . In addition, expression of Bclx L, a gene activated by NF-κB, was higher in cells expressing MUC1 (Fig. 1d) . To determine whether MUC1 affects IκBα phosphorylation (as phosphorylated IκBα is targeted for ubiquitination and proteosomal degradation) cytosolic lysates were immunoblotted with an anti-phospho-IκBα antibody. Indeed, phospho-IκBα levels were significantly higher in cells expressing MUC1 (Fig. 1e) . Assessment of IκBα stability indicated that MUC1 expression increases degradation of IκBα (Fig. 1f) . The halflives of IκBα in the absence and presence of MUC1, were 6.7 ± 0.5 h and 3.8 ± 0.3 h (mean ± s.d., n = 3), respectively. Similar results were obtained in ZR-75-1 cells (data not shown), indicating that MUC1-induced increases in phosphorylation of IκBα are associated with increases in IκBα degradation. Targeting of NF-κB p65 to the nucleus activates IκBα gene transcription in an inducible, autoregulatory pathway that replenishes IκBα levels 1, 2 . Consistent with this autoregulatory loop, RT-PCR analysis demonstrated that MUC1-induced increases in nuclear NF-κB p65 are associated with upregulation of IκBα mRNA levels (Fig. 1g) . These findings indicate that MUC1 contributes to IκBα degradation, resulting in activation of NF-κB p65.
Nuclear factor-κB (NF-κB) is constitutively activated in diverse human malignancies by mechanisms that are not understood 1, 2 . The MUC1 oncoprotein is aberrantly overexpressed by most human carcinomas and, similarly to NF-κB, blocks apoptosis and induces transformation [3] [4] [5] [6] . This study demonstrates that overexpression of MUC1 in human carcinoma cells is associated with constitutive activation of NF-κB p65. We show that MUC1 interacts with the highmolecular-weight IκB kinase (IKK) complex in vivo and that the MUC1 cytoplasmic domain binds directly to IKKβ and IKKγ. Interaction of MUC1 with both IKKβ and IKKγ is necessary for IKKβ activation, resulting in phosphorylation and degradation of IκBα. Studies in non-malignant epithelial cells show that MUC1 is recruited to the TNF-R1 complex and interacts with IKKβ-IKKγ in response to TNFα stimulation. TNFα-induced recruitment of MUC1 is dependent on TRADD and TRAF2, but not the death-domain kinase RIP1. In addition, MUC1-mediated activation of IKKβ is dependent on TAK1 and TAB2. These findings indicate that MUC1 is important for physiological activation of IKKβ and that overexpression of MUC1, as found in human cancers, confers sustained induction of the IKKβ-NF-κB p65 pathway.
Nuclear localization of NF-κB p65 was studied in HCT116 colon cancer and HeLa cervical cancer cells that stably express either an empty vector or MUC1 (ref. 4 , also see Supplementary Information, Fig. S1a ). Levels of nuclear NF-κB p65 were lower in vector cells than in cells expressing MUC1 (Fig. 1a) . Human ZR-75-1 and MCF-7 breast cancer cells that express endogenous MUC1 were stably transfected to express either an empty vector or a MUC1 siRNA 4 ( Supplementary Information, Fig. S1a ). Silencing of MUC1 in ZR-75-1 (ref. 4 ) and MCF-7 cells 7 decreased nuclear NF-κB p65 (Fig. 1b) . MUC1 expression was also associated with a decrease in cytosolic NF-κB p65 levels in HeLa and ZR-75-1 cells ( Supplementary  Information, Fig. S1b ). To determine whether MUC1 is associated with activation of the NF-κB p65 transcription function, HeLa and ZR-75-1 cells were transfected with a construct containing a NF-κB-binding site upstream of the luciferase reporter (pNF-κB-Luc). MUC1 expression was associated with activation of pNF-κB-Luc (Fig. 1c) . In contrast, MUC1 had no effect on activation of a pNF-κB-Luc construct that was mutated at the NF-κB p65 binding site (Fig. 1c) . In addition, expression of Bclx L, a gene activated by NF-κB, was higher in cells expressing MUC1 (Fig. 1d ). To determine whether MUC1 affects IκBα phosphorylation (as phosphorylated IκBα is targeted for ubiquitination and proteosomal degradation) cytosolic lysates were immunoblotted with an anti-phospho-IκBα antibody. Indeed, phospho-IκBα levels were significantly higher in cells expressing MUC1 (Fig. 1e) . Assessment of IκBα stability indicated that MUC1 expression increases degradation of IκBα (Fig. 1f) . The halflives of IκBα in the absence and presence of MUC1, were 6.7 ± 0.5 h and 3.8 ± 0.3 h (mean ± s.d., n = 3), respectively. Similar results were obtained in ZR-75-1 cells (data not shown), indicating that MUC1-induced increases in phosphorylation of IκBα are associated with increases in IκBα degradation. Targeting of NF-κB p65 to the nucleus activates IκBα gene transcription in an inducible, autoregulatory pathway that replenishes IκBα levels 1, 2 . Consistent with this autoregulatory loop, RT-PCR analysis demonstrated that MUC1-induced increases in nuclear NF-κB p65 are associated with upregulation of IκBα mRNA levels (Fig. 1g) . These findings indicate that MUC1 contributes to IκBα degradation, resulting in activation of NF-κB p65.
The presence of IKKβ in a complex with IKKγ is necessary and sufficient for phosphorylation of IκBα in the classical NF-κB pathway. IKKγ binds directly to IKKβ and is required for IKKβ activation. Analysis of anti-IKKβ immunoprecipitates from ZR-75-1 and MCF-7 cells showed that MUC1 carboxy-terminal subunit (MUC1-C) associates with IKKβ (Fig. 2a) . In vitro studies with purified GST-IKKβ and the MUC1 cytoplasmic domain (MUC1-CD) demonstrated that these proteins interact directly with each other (Fig. 2b) . This interaction was confirmed in experiments with purified GST-MUC1-CD and IKKβ (Fig. 2c , lower left). Studies with MUC1-CD amino acid fragments 1-45 and 46-72 demonstrated that MUC1-CD(1-45) confers binding to IKKβ (Fig. 2c, left) . Studies with IKKβ(1-458) and IKKβ(458-756) further demonstrated that MUC1-CD binds directly to the IKKβ-amino-terminal region (Fig. 2c, lower right) . The IKKβ-carboxy-terminal region associates with the N-terminal region of IKKγ. Consistent with the formation of IKKβ-IKKγ complexes and binding of MUC1 to IKKβ, we found that MUC1-C co-precipitates with IKKγ (Fig. 2d) . In vitro studies with GST-IKKγ demonstrated that MUC1-CD binds to purified IKKγ (Fig. 2e) . In contrast to the interaction with IKKβ, MUC1-CD(46-72) but not MUC1-CD(1-45) binds to IKKγ (Fig. 2f) and at the C-terminal region of IKKγ (Fig. 2g) . To further assess binding of MUC1-C to IKKβ and IKKγ in vivo, MUC1-C was immunodepleted from HeLa-MUC1 cell lysates by precipitation with increasing amounts of an anti-MUC1-C antibody ( Supplementary Information, Fig. S1c, left) . As a control, the lysates were incubated with a non-immune IgG ( Supplementary   Information, Fig. S1c, right) . Immunoblot analysis of the lysates demonstrated that depletion of MUC1-C is associated with decreases in IKKβ and IKKγ (Supplementary Fig. S1c ). These findings indicate that MUC1 binds directly to IKKβ and IKKγ, and potentially to both proteins in IKKβ-IKKγ complexes ( Supplementary Information, Fig. S1d ).
To determine whether MUC1-C associates with the IKK complex, lysates from HeLa-vector and HeLa-MUC1 cells were subjected to gel filtration chromatography followed by immunoblotting of the fractions with anti-IKKβ and anti-IKKγ antibodies. Consistent with previous findings 8 , analysis of HeLa-vector cells showed that IKKβ and IKKγ are detectable in a prominent pool with a relative molecular mass (M r ) of 700,000 (fractions 10-12) and also in a pool of ~300 K (fractions 14 and 15; Fig. 3a ). Analysis of HeLa-MUC1 cells showed that IKKβ and IKKγ are detectable in fractions 10-12 but not in fractions 14 and 15 ( Fig. 3a) . MUC1-C was detected mainly in fraction 10, consistent with binding to the large ~700-K complex (Fig. 3a) . The ~700-K IKKβ-IKKγ complexes isolated from HeLa-MUC1, but not HeLa-vector cells, exhibited constitutive activation (Fig. 3a) . The HeLa-MUC1 lysates were also immunoprecipitated with an anti-MUC1-C antibody and the precipitates were released by adding MUC1-C peptide before gel filtration chromatography. Immunoblot analysis of the fractions confirmed that MUC1-C associates with the large IKKβ-IKKγ complexes ( Supplementary Information,  Fig. S2a ). MUC1 expression was associated with increased binding of IKKβ to IKKγ (Fig. 3b) . Moreover, incubation of purified IKKβ with IKKγ in vitro demonstrated that MUC1-CD increases the interaction between IKKβ and IKKγ (Fig. 3c) . MUC1-CD(1-45) binds to IKKβ and MUC1-CD(46-72), which contains a serine-rich SAGNGGSSLS motif (SRM; amino acids 50-59), binds to IKKγ (Fig. 2) . Mutation of the SRM to AAGNGGAAAA (mSRM) had no effect on the interaction between MUC1-CD and IKKβ ( Supplementary Information, Fig. S2b ), but attenuated binding to IKKγ ( Supplementary Information, Fig. S2c ). MUC1-CD(mSRM) was substantially less effective than MUC1-CD in inducing the association of IKKβ and IKKγ (Fig. 3c) , indicating that this response is dependent on binding of both IKKs to MUC1-CD. Phosphorylation of IKKβ on Ser 181 in the activation loop, perhaps by a trans-autophosphorylation mechanism, is required for induction of IKKβ activity. Immunoblot analysis with an anti-phospho-IKKβ-Ser 181 antibody showed that IKKβ is phosphorylated on Ser 181 by a MUC1-dependent mechanism (Fig. 3d) . Analysis of anti-IKKβ precipitates for phosphorylation of IκBα further demonstrated that MUC1 stimulates the IKKβ kinase function (Fig. 3e) . Incubation of IKKβ and IKKγ with ATP in vitro resulted in phosphorylation of IKKβ on Ser 181 (Fig. 3f) . The extent of IKKβ phosphorylation was increased significantly by adding MUC1-CD to the reaction (Fig. 3f) . However, this effect of MUC1-CD was attenuated by mutation of the SRM (Fig. 3f) . Fig. S3e ). Expression of MUC1-CD (mSRM) was less effective than MUC1-CD in inducing the formation of IKKβ-IKKγ complexes ( Supplementary Information, Fig. S3b ). MUC1-CDinduced phosphorylation of IKKβ on Ser 181, phosphorylation of IκBα and targeting of NF-κB p65 to the nucleus were each attenuated by mutation of the SRM ( Supplementary Information, Figs. S3c-e) . These findings indicate that MUC1-CD is sufficient to activate the classical IKKβ-NF-κB p65 pathway. Binding of MUC1-C to the IKKβ-IKKγ complex may represent a physiological response in non-transformed cells that is constitutively activated by the overexpression of MUC1 in carcinoma cells. To address this hypothesis, studies were performed on the non-transformed mammary epithelial cell line, MCF-10A 9, 10 , in which MUC1 is expressed at levels lower than those found in MCF-7 and ZR-75-1 cells ( Supplementary Information, Fig. S4a ) and where binding of MUC1-C to IKKβ or IKKγ is minimal ( Supplementary Information, Fig. S4b ). IKKβ and IKKγ are responsible for signalling to NF-κB in the response to tumour necrosis factor alpha (TNFα) and other pro-inflammatory Supplementary Information, Fig. S4b ). In contrast, TNFα had no apparent effect on binding of MUC1-C to IKKβ or IKKγ in MCF-7 cells (data not shown). Treatment of MCF-10A cells with TNFα was also associated with phosphorylation and degradation of IκBα (Fig. 4a) , and targeting of NF-κB p65 to the nucleus (Fig. 4a) . Transient silencing of MUC1 attenuated phosphorylation of IKKβ on Ser 181, phosphorylation of IκBα and nuclear targeting of NF-κB p65 in the response to TNFα stimulation (Fig. 4b) . Previous work has demonstrated that the effects of TNFα on mammary epithelial cells are of physiological importance for mammary gland morphogenesis during puberty and pregnancy [11] [12] [13] [14] [15] . To determine whether these effects of TNFα are regulated by MUC1, primary mouse mammary epithelial cells (MMECs) were transfected with control or mouse-specific Muc1 siRNAs (Fig. 4c) . Silencing of Muc1 in MMECs blocked TNFα-induced phosphorylation of IKKβ and IκBα (Fig. 4c) . Muc1 was also necessary for TNFα-induced targeting of NF-κB p65 to the nucleus (Fig. 4c) .
Binding of TNFα to TNF-R1 is associated with the recruitment of TNF-R1-associated death domain protein (TRADD) and TNF receptor-associated factor 2 (TRAF2) to the receptor complex 2 . In turn, TRAF2 recruits IKKs to the complex. Stimulation of MCF-10A cells with TNFα induced the association of MUC1-C with TNF-R1, TRADD and TRAF2 ( Supplementary Information, Fig. S4c ), indicating that MUC1-C is recruited to the TNF-R1 complex. Silencing of TRADD or TRAF2 demonstrated that both of these proteins are required for TNFα-induced recruitment of MUC1-C (Fig. 4d) . The death-domain kinase receptorinteracting protein 1 (RIP1) is also recruited to the TNF-R1 complex, where it functions as a scaffold for IKK activation 2 . Notably, silencing of RIP1 had little, if any, effect on the recruitment of MUC1-C (Fig. 4d) . Silencing of TRADD or TRAF2, but not RIP1, also blocked the TNFα-induced association of MUC1-C with IKKβ (Fig. 4e) . In TNFα-treated fibroblasts, HeLa cells and Jurkat cells [16] [17] [18] [19] [20] , which are null for MUC1 expression 6, 21, 22 , RIP1 mediates IKK activation by binding directly to IKKγ and is essential for induction of NF-κB signalling. In contrast, we found that silencing of RIP1 in MCF-10A cells had little effect on TNFα-induced activation of NF-κB p65 (Fig. 4f) . These results indicate that in MCF-10A cells, TNFα recruits MUC1-C to the TNF-R1 complex by a TRADD-and TRAF2-dependent mechanism and that MUC1-C functions independently of RIP1 in the activation of IKKβ.
To determine whether MUC1-dependent phosphorylation of IKKβ on Ser 181 is mediated by transforming growth factor-β-activated kinase 1 (TAK1), which phosphorylates IKKβ on Ser 181 and activates the NF-κB pathway in response to TNFα stimulation 23, 24 , TAK1 was silenced in MCF-10A cells (Fig. 5a ). These results demonstrate that TNFα stimulation is associated with phosphorylation of IKKβ on Ser 181 by a TAK1-mediated mechanism (Fig. 5a ). TNFα-induced phosphorylation of IκBα and targeting of NF-κB p65 to the nucleus were also dependent on TAK1 (Fig. 5a) . The TAK1-binding proteins TAB1, TAB2 and TAB3 function as adaptor molecules in linking TRAFs to TAK1 activation 23, 25, 26 . Silencing of TAB1 in MCF-10A cells had no effect on TNFα-induced phosphorylation of IKKβ on Ser 181, phosphorylation and degradation of IκBα, or targeting of NF-κB p65 to the nucleus ( Supplementary Information,  Fig. S5 ). However, silencing of TAB2 (Fig. 5b) , but not its homologue TAB3 (ref. 26 and data not shown), was associated with attenuation of TNFα-induced phosphorylation of IKKβ on Ser 181 and activation of the NF-κB p65 pathway. In this regard, TAB2 but not TAB1, is critical for TNFα signalling 23, 27, 28 . Together with our other findings, these results support a model in which MUC1-C is necessary for TNFα-induced recruitment of TAK1 to the TNF-R1 complex. Consistent with such a model, silencing of MUC1 blocked recruitment of TAK1 to TNF-R1 in TNFα-stimulated MCF-10A cells (Fig. 5c, upper) . Notably, studies in Jurkat cells have shown that RIP1 is necessary for recruitment of TAK1 to the TNF-R1 complex 29 . Our studies showed that silencing of RIP1 in MCF-10A cells had little, if any effect, on recruitment of TAK1 to TNF-R1 (Fig. 5c, lower) . This indicates that MUC1, but not RIP1, is essential for TNFα-induced TAK1 phosphorylation of IKKβ. Silencing of MUC1 in MCF-10A cells was also associated with TNFα-induced apoptosis (Fig. 5d) , a response blocked by activation of the NF-κB pathway 30 . These findings indicate that MUC1 is involved in activation of TAK1-IKKβ-NF-κB p65 signalling by TNFα and thereby attenuation of the apoptotic response.
The present studies support a model in which MUC1-C binds directly to IKKβ and IKKγ to activate the IKK complex (Fig. 5e) . As shown for heat shock proteins, which associate with multiple targets 31 , the evidence to date indicates that MUC1-C maintains effectors of growth and survival pathways (β-catenin, p53) and nuclear hormone receptors (ERα) in stabilized and active configurations [4] [5] [6] [7] . We found that expression of MUC1 in carcinoma cells constitutively induces multiple processes, including the formation of IKKβ-IKKγ complexes, phosphorylation of IKKβ on Ser 181, IKKβ-mediated phosphorylation of IκBα and targeting of NF-κB p65 to the nucleus (Fig. 5e) . A variety of human tumours aberrantly overexpress MUC1 and exhibit constitutive activation of the NF-κB pathway 21, [32] [33] [34] . The present findings indicate that MUC1 may contribute, at least in part, to activation of NF-κB in these tumours to promote cell survival. Studies performed in non-malignant MCF-10A mammary epithelial cells demonstrate that MUC1-C associates with the TNF-R1 complex in the response to TNFα stimulation and functions in the recruitment of TAK1, TAK1-mediated phosphorylation of IKKβ, assembly of the IKKβ-IKKγ complex and trans-autophosphorylation of IKKβ. Our results also indicate that TAB2 is necessary for MUC1-C function, whereas RIP1 is not required for TNFα-induced recruitment of MUC1-C to the TNF-R1 complex, binding of MUC1-C to IKKβ or activation of NF-κB. Moreover, MUC1, and not RIP1, was shown to be necessary for recruitment of TAK1 to the TNF-R1 complex. These findings indicate that MUC1-C functions independently of RIP1 in TNFα-induced IKKβ activation. The findings further indicate that there may be more than one IKK complex, depending on cell type, and that the binding partner (for example RIP1 or MUC1-C) may vary, depending on availability and affinity for the IKKs. In summary, our findings indicate that overexpression of MUC1 as found in human tumours is important for sustained IKKβ-NF-κB signalling and that MUC1-mediated activation of this pathway may be exploited by malignant cells for survival under adverse conditions.
MeThoDS
Cell culture. Human HCT116 colon carcinoma cells, HeLa cervical carcinoma cells and MCF-7 breast-cancer cells were grown in Dulbecco's modified Eagle's medium with 10% heat-inactivated fetal bovine serum, 100 U ml -1 penicillin, 100 μg ml Subcellular fractionation. Nuclear and cytosolic fractions were prepared as previously described [3] [4] [5] [6] .
Immunoprecipitation and immunoblotting.
Lysates from sub-confluent cells were prepared as previously described ; Perkin-Elmer Life Sciences, Waltham, MA) for 1 h, washed and then chased in the presence of complete medium. Anti-IκBα precipitates were subjected to SDS-PAGE and autoradiography. Intensity of the signals was determined by densitometric scanning.
RT-PCR.
Total cellular RNA was extracted with the High Pure RNA Isolation kit (Roche, Indianapolis, IN). IκBα-specific (5ʹ-AGTCCTGCACCACCCCGCACC-3ʹ and 3ʹ-TCATAACGTCAGACGCTGGCCTC-5ʹ), mouse Muc1-specific (5ʹ-CCACCTCACACACGGAGCGC-3 and 3ʹ-GTCATCAGGTGTCACCGTGG-5), human β-actin and mouse β-actin (5ʹ-CTGTCGAGTCGCGTCCACCC-3ʹ and 3ʹ-TGGTGTCCGTAACACTACCT-5ʹ) primers were used for reverse transcription and amplification (SuperScript One-Step RT-PCR with Platinum Taq; Invitrogen). Amplified fragments were analysed by electrophoresis in 2% agarose gels.
In vitro binding assays. Purified GST-MUC1-CD was cleaved with thrombin to remove the GST moiety. GST, GST-IKKβ, GST-IKKβ(1-458), GST-IKKβ(458-756), GST-IKKγ, GST-IKKγ or GST-IKKγ(197-419) was then incubated with the MUC1-CD for 1 h at 25 º C. In other experiments, GST, GST-MUC1-CD, GST-MUC1-CD(1-45), GST-MUC1-CD(46-72) or GST-MUC1-CD(mSRM) were incubated with purified IKKβ or IKKγ. Adsorbates to glutathione-conjugated beads were analysed by immunoblotting.
Protein gel filtration chromatography. HeLa-vector and HeLa-MUC1 cells were lysed in 50 mM Tris-HCl, at pH 7.5, 150 mM NaCl, 1 mM NaVO 3 , 1 mM phenylmethylsulphonyl fluoride (PMSF), 1 mM dithiothreitol (DTT), 10 mM NaF, 10 µg µl -1 aprotinin and 10 µg µl -1 leupeptin for 15 min at 4 º C. The lysates were sedimented at 14,000 g for 15 min to remove the insoluble fraction. Soluble protein (500 mg) was injected into a Sephacryl S-200 HR column and separated by fast protein liquid chromatography (FPLC) using the lysis buffer. Thirty fractions of 4 ml each were collected and 40 μl aliquots were subjected to immunoblot analysis.
In vitro kinase assays. IKK complexes were immunoprecipitated with anti-IKKβ antibody. The precipitates were incubated in 50 mM HEPES (pH 7.4), 10 mM MgCl 2 , 10 mM MnCl 2 , 2 mM DTT, 0.1 mM NaF, 10 µM ATP, 0.4 μCi µl -1 32 P-ATP (Perkin-Elmer Life Sciences) and 0.1 μg μl -1 purified GST-IκBα(1-54) for 30 min at 30 º C. The reaction products were analysed by SDS-PAGE and autoradiography.
Isolation of mouse mammary epithelial cells (MMECs).
The fourth and fifth mammary glands were resected from 8-week-old virgin C57BL/6 female mice, minced and digested in 0.2% collagenase I, 0.2% trypsin and 5% fetal bovine serum in mammary epithelial basal medium (Lonza) for 2 h at 37 º C as described 35 . The cells were pelleted at 469 g, washed in mammary epithelial basal medium (Lonza) for 10 cycles and then seeded in MEGM (Lonza). 
Transfection of

